Phibro Animal Health Corporation (NASDAQ:PAHC) is making waves as one of the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds. The company recently received an upgrade from Morgan Stanley, which increased its price target on PAHC to $49 from $45 while maintaining an Equal Weight rating. This upgrade came on the heels of strong operational performance in the company’s latest quarterly results, with significant margin expansion and a better fiscal 2026 forecast.
Morgan Stanley highlighted Phibro Animal Health Corporation’s effective execution within the Animal Health segment and progress related to the Zoetis MFA transaction. The firm also noted disciplined cost control as a significant factor contributing to the company’s success. Recent outcomes show strong momentum in several key business areas, indicating a positive trajectory for PAHC.
Furthermore, Phibro Animal Health Corporation recently revealed its fiscal second-quarter results for the fiscal year ending on December 31, 2025. The report showcased impressive year-over-year improvement, with net sales rising by 21% to $373.9 million and net income increasing to $27.5 million. Adjusted EBITDA saw a substantial increase of 41% to $68.1 million, while adjusted diluted EPS rose by 58% to $0.87.
The strong performance in the second quarter led to an increase in Phibro Animal Health Corporation’s fiscal 2026 estimates. The company updated its full-year net sales estimates to $1.45 billion to $1.50 billion and adjusted EBITDA to $245 million to $255 million, reflecting improved operating momentum and increased profitability forecasts for the remainder of the year.
Phibro Animal Health Corporation is a global animal health and nutrition company that focuses on developing and marketing vaccines, medicated feed additives, trace minerals, and specialty products to enhance livestock and companion animal health. While PAHC shows promise as an investment, there are other AI stocks with greater upside potential and less downside risk.
For investors seeking an undervalued AI stock that could benefit from Trump-era tariffs and the onshoring trend, exploring the best short-term AI stock might be worth considering. As always, it’s essential to conduct thorough research and consider all factors before making investment decisions.
In conclusion, Phibro Animal Health Corporation’s recent success and positive outlook make it a company worth watching in the pharmaceutical industry. With strong operational performance, margin expansion, and increased profitability forecasts, PAHC is positioning itself for continued growth and success in the coming years.
Disclosure: None.
